06 Jun 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Leading Indian drug maker from Mumbai, Glenmark has opened a new mAb manufacturing facility in Switzerland. This is in line with the company on-going work on both novel monoclonal antibodies and biosimilars and the need for more manufacturing capacity for its clinical trial work.
Reports have explained how many companies have undertaken expansion projects with more mAbs and antibody-drug conjugates being developed for attacking cancers.
Glenmark Biologics President Michael Buschle explained that the company has a number of mAbs in various stages of development, including bispecific antibodies, and so needed more capacity. "The manufacturing facility would help us bring these antibodies to the clinic faster and position Glenmark as a leading innovative pharmaceutical company," he said in a statement.
The manufacturing facility is in La Chaux-de-Fonds, Switzerland, where Glenmark has an integrated research center for antibody discovery and development. The new manufacturing facility will employ single-use bioreactor systems and also includes a suite for manufacturing cell banks. The company has not disclosed any financial details about investment into the new facility. It is said to have employed 69 people there.